BlackRock
HUMA icon

BlackRock’s Humacyte HUMA Stock Holding History

BlackRock’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.78M Sell
4,839,929
-7,477,026
-61% -$6.93M ﹤0.01% 4006
2026
Q1 		$7.47M Buy
12,316,955
+971,836
+9% +$1.01M ﹤0.01% 3664
2025
Q4 		$10.9M Buy
11,345,119
+1,443,324
+15% +$2.04M ﹤0.01% 3418
2025
Q3 		$17.2M Sell
9,901,795
-43,653
-0.4% -$85.5K ﹤0.01% 3169
2025
Q2 		$20.8M Buy
9,945,448
+1,720,304
+21% +$3.3M ﹤0.01% 2998
2025
Q1 		$14M Buy
8,225,144
+177,559
+2% +$667K ﹤0.01% 3138
2024
Q4 		$40.6M Buy
8,047,585
+508,246
+7% +$2.51M ﹤0.01% 2587
2024
Q3 		$41M Buy
7,539,339
+399,325
+6% +$2.63M ﹤0.01% 2596
2024
Q2 		$34.3M Buy
7,140,014
+2,351,274
+49% +$12.2M ﹤0.01% 2653
2024
Q1 		$14.9M Sell
4,788,740
-110,549
-2% -$372K ﹤0.01% 3147
2023
Q4 		$13.9M Buy
4,899,289
+398,803
+9% +$1.02M ﹤0.01% 3217
2023
Q3 		$13.2M Buy
4,500,486
+195,981
+5% +$648K ﹤0.01% 3165
2023
Q2 		$12.3M Buy
4,304,505
+501,265
+13% +$1.81M ﹤0.01% 3315
2023
Q1 		$11.8M Sell
3,803,240
-207,162
-5% -$589K ﹤0.01% 3233
2022
Q4 		$8.46M Buy
4,010,402
+1,799,047
+81% +$5.46M ﹤0.01% 3471
2022
Q3 		$7.21M Sell
2,211,355
-185,023
-8% -$710K ﹤0.01% 3593
2022
Q2 		$7.69M Buy
2,396,378
+818,459
+52% +$4.55M ﹤0.01% 3630
2022
Q1 		$11.1M Buy
1,577,919
+176,846
+13% +$1.03M ﹤0.01% 3519
2021
Q4 		$10.2M Buy
+1,401,073
New +$13.9M ﹤0.01% 3665

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BlackRock's HUMA Position: Q2 2026 in Review

BlackRock reduced its Humacyte (HUMA) stake by 61% in Q2 2026, selling an estimated $6.93M and leaving 4,839,929 shares worth $3.78M. The position accounts for ﹤0.01% of the portfolio, ranked #4006.

BlackRock first reported a position in HUMA in Q4 2021 and has held it in 19 quarters since. The position peaked at $41M in Q3 2024. 162 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • BlackRock held 4,839,929 shares of Humacyte worth $3.78M as of Q2 2026.
  • BlackRock sold 7,477,026 Humacyte shares in Q2 2026, an estimated $6.93M.
  • Humacyte made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4006 holding.
  • BlackRock first reported a position in Humacyte in Q4 2021 and has held it in 19 quarters since.
  • BlackRock's Humacyte position peaked at $41M in Q3 2024.
  • 162 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.